Company intelligence / Profile preview

Therorna

Ownership: Private
Development stage: Preclinical

Overview

Therorna has completed a $42 million Series A funding round aimed at accelerating development of circRNA-based broad-spectrum COVID-19 vaccines and other innovative therapies. The circRNA platform offers advantages over linear mRNA in stability, expression duration, immunogenicity, and production efficiency. The company has established a strong pipeline targeting unmet medical needs using this novel modality

Therapeutic areas: Infectious Diseases
Modalities: Circular RNA technology platform, focusing on RNA-based therapeutics and vaccines, including prophylactic and therapeutic new drug products
Industry: Biotech

Drug pipeline

11 assets

TI-0010

10 more assets in the full pipeline.

Beyond the preview

Go deeper on Therorna.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Therorna.